Pharmaceuticals

GINWA

GINWA released FY2025 Q3 earnings on October 29 During-Market BJT, actual revenue CNY 142.62 M, actual EPS CNY 0.0799

GINWA released FY2025 9 Months Earnings on October 29 During-Market (BJT), actual revenue CNY 383.91 M, actual EPS CNY 0.0977

GINWA to Release FY2025 Q3 Earnings Report on October 30 During-Market BJT

GINWA released FY2025 Q2 earnings on August 21 During-Market (BJT), actual revenue CNY 133.97 M, actual EPS CNY 0.0143

GINWA released FY2025 Semi-Annual Earnings on August 21 During-Market (BJT), actual revenue CNY 241.29 M, actual EPS CNY 0.0176

GINWA to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Jinhua Group Chairman Xing Yajiang Reinvestigated for Breach of Disclosure Rules

Chairman of Jinghua Co. Investigated by CSRC for Violations in Shareholding Changes Disclosure

Jinhua Pharmaceutical Chairman Xiaojun Xing Investigated for Disclosure Violations

New Yu Jinyu Reduced Shares in Jinhua Co. to 4.999996%

Jinhua Co. Fully Subsidiary Founded Hanzhong Jinhua Pharmaceutical Technology Co.

Jinhua Pharmaceutical's Jintiange Capsule Granted Extended Second-Level Protection

Jinhua Pharmaceutical Reports 7.31% Q1 Revenue Decline and 94.93% YoY Drop in Net Profit

GINWA released FY2024 earnings on April 24 Pre-Market (BJT), actual revenue CNY 585.46 M, actual EPS CNY 0.2088

GINWA released FY2024 Q4 earnings on April 24 Pre-Market (BJT), actual revenue CNY 166.53 M, actual EPS CNY 0.1326

GINWA released FY2025 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 107.32 M, actual EPS CNY 0.0034

GINWA FY2025 Q1 Earnings Release Scheduled for April 25 After-Market BJT

GINWA to Release FY2024 Annual Earnings on April 25 Pre-Market BJT

Chairman of Jinhua Co., Ltd. Xing Yajiang Filed for Violating Information Disclosure

GINWA released FY2024 9 Months Earnings on October 29 After-Market (BJT), actual revenue CNY 418.93M, actual EPS CNY 0.0809

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

Earning Release Date

财报预告

FY2025 Annual Earning Release 2026.04.29 After-Market

Xingqi Pharmaceutical

Hengrui Pharma

Yunnan Baiyao

Salubris

Haisco

CR Sanjiu

Allist

Asymchem

DEEJ

LIVZON GROUP

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

600080

GINWA plans to reduce its repurchased shares by no more than 2% through centralized bidding, expecting to reduce no more than 7,465,405 shares, mainly to supplement working capital. The company repurchased 20,557,582 shares from February 23, 2024, to May 22, 2024, accounting for 5.51% of the total share capital. After the reduction, the shares held in the repurchase special account will decrease to 13,092,177 shares, accounting for 3.51%

Zhitong

GINWA: Plans to reduce holdings by no more than 2% of repurchased shares to supplement working capital

GINWA announced that the company has received the remaining transfer payment of RMB 149 million and the interest of RMB 6.5231 million generated from the deferred payment from Western Investment Group Co., Ltd., totaling RMB 155 million. Thus, the company has received a total of RMB 351 million in transfer payments and interest for the 100% equity transfer of GINWA International Hotel from Western Group, and this transaction has been fully completed. Subsequently, the company will handle the relevant procedures for the release of mortgages and pledges according to the agreement

GINWA: The full transfer payment and interest for 100% equity of GINWA International Hotel have been received

GINWA announced that in the first half of 2025, operating revenue was 241 million yuan, a year-on-year decrease of 1.90%. Net profit was 6.195 million yuan, a year-on-year decrease of 34.53%. No profit distribution or transfer of reserves to increase share capital will be conducted during the reporting period

GINWA: Net profit of 6.195 million yuan in the first half of 2025, a year-on-year decrease of 34.53%

The China Securities Regulatory Commission fined Ginwa Enterprise Group's chairman, Xing Yajiang, 3.5 million yuan for failing to disclose his residential surveillance by public security authorities from April to July 2024. This violation was only reported on August 23, 2024. The company stated that this issue will not significantly affect its daily operations, although its shares fell by less than 5%.

Trading View

Ginwa Enterprise's Chairman Slapped With 3.5 Million Yuan Fine on Disclosure Violations

The chairman of GINWA, Xing Yajiang, received a notice of case filing from the China Securities Regulatory Commission on May 23, 2025, for suspected violations of information disclosure laws and regulations. This case filing is only against Xing Yajiang personally and will not affect the company's daily operations; the company is currently operating normally

Chairman of GINWA, Xing Yajiang, received a notice of case filing from the China Securities Regulatory Commission

According to the Zhitong Finance APP, GINWA announced that on May 19, 2025, the company received a "Notice Letter" from shareholder Xinyu Jinyu, stating that from February 18, 2025, to May 17, 2025, shareholder Xinyu Jinyu cumulatively reduced its holdings of the company's shares by 133,500 shares (accounting for 0.035765% of the company's total share capital), and the time period for this reduction plan has expired

GINWA's shareholder Xinyu Jinyu has cumulatively reduced his holdings by 133,500 shares

According to the Qichacha APP, recently, Hanzhong Jinhua Pharmaceutical Technology Co., Ltd. was established, with Hou Junting as the legal representative and a registered capital of 50 million yuan. The business scope includes: pharmaceutical wholesale; pharmaceutical retail; pharmaceutical import and export; internet information services for medical devices, etc. Qichacha's equity penetration shows that the company is wholly owned by GINWA

GINWA established a new pharmaceutical technology company

GINWA announced that the National Medical Products Administration has approved the extension of the secondary protection period for its Jintian Ge capsules under the national protection of traditional Chinese medicine to February 25, 2032. This medication is used to improve symptoms such as lower back pain, and the extension of the protection period will enhance the company's core competitiveness in the orthopedic field, positively impacting its production and operations

Yinhua CSI Chinese Medicine ETF

GINWA: Jintian Ge capsules approved for extended protection period of national traditional Chinese medicine protection varieties

According to the Zhitong Finance APP, GINWA disclosed its first-quarter report for 2025, showing that the company achieved revenue of 107 million yuan during the reporting period, a year-on-year decrease of 7.31%; the net profit attributable to shareholders was 1.22 million yuan, a year-on-year decrease of 94.93%; the net profit excluding non-recurring items was 10.67 million yuan, a year-on-year increase of 151.79%. The basic earnings per share were 0.0034 yuan

GINWA released its first-quarter performance, with a net profit attributable to the parent company of 1.22 million yuan, a year-on-year decrease of 94.93%

GINWA announced that shareholder Xinyu Jinyu reduced its holdings by 133,500 shares through centralized bidding on February 18, 2024, bringing its shareholding ratio down to 4.999996%, no longer being a shareholder with over 5%

GINWA's shareholder Xinyu Jinyu's shareholding has dropped to below 5%

According to the Zhitong Finance APP, GINWA announced that the company's chairman, Xing Yajiang, received a "Notice of Case Filing" (No.: Zhen Jian Li An Zi 0092024002) from the China Securities Regulatory Commission on December 20, 2024. Due to suspected violations of information disclosure laws and regulations, the China Securities Regulatory Commission decided to file a case against the company's chairman, Xing Yajiang, in accordance with the Securities Law of the People's Republic of China, the Administrative Penalty Law of the People's Republic of China, and other laws and regulations

Chairman of GINWA, Xing Yajiang, is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws

GINWA(600080.SH)

GINWA Stock Performance Chart

Financial Score

Valuation analysis

Institutional View & Shareholder

Analyst Ratings

GINWA: Plans to reduce holdings by no more than 2% of repurchased shares to supplement working capital

GINWA: The full transfer payment and interest for 100% equity of GINWA International Hotel have been received

GINWA: Net profit of 6.195 million yuan in the first half of 2025, a year-on-year decrease of 34.53%

Ginwa Enterprise's Chairman Slapped With 3.5 Million Yuan Fine on Disclosure Violations

Chairman of GINWA, Xing Yajiang, received a notice of case filing from the China Securities Regulatory Commission

Trending